Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $400.00 price target on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the company. Barclays increased their price objective […]
More Stories
Capital Management Corp VA Cuts Stock Position in Molson Coors Beverage (NYSE:TAP)
Capital Management Corp VA decreased its stake in shares of Molson Coors Beverage (NYSE:TAP – Free Report) by 18.6% during...
UBS Group Issues Positive Forecast for Broadcom (NASDAQ:AVGO) Stock Price
Broadcom (NASDAQ:AVGO – Free Report) had its price objective upped by UBS Group from $170.00 to $200.00 in a research...
Capital Management Corp VA Has $23.60 Million Stock Position in Service Properties Trust (NASDAQ:SVC)
Capital Management Corp VA grew its stake in Service Properties Trust (NASDAQ:SVC – Free Report) by 9.6% in the third...
Amalgamated Bank Reduces Stake in The Southern Company (NYSE:SO)
Amalgamated Bank reduced its position in The Southern Company (NYSE:SO – Free Report) by 1.4% in the 3rd quarter, according...
Clarity Financial LLC Purchases 640 Shares of Vanguard Total Stock Market ETF (NYSEARCA:VTI)
Clarity Financial LLC lifted its position in shares of Vanguard Total Stock Market ETF (NYSEARCA:VTI – Free Report) by 18.9%...
Yacktman Asset Management LP Grows Stake in The Clorox Company (NYSE:CLX)
Yacktman Asset Management LP increased its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 1.0% in...